Tempus AI (TEM) traded higher Thursday as traders positioned ahead of the company’s first-quarter 2026 earnings release, which is set for Tuesday, May 5, 2026, after the close, followed by a 4:30 p.m. ET conference call and webcast. With a near-term catalyst on the calendar, the stock’s move fits a pre-earnings repricing dynamic common in high-beta, growth-oriented healthcare AI names.

Tempus has already told investors it will report Q1 2026 results on May 5, putting near-term focus on revenue growth, diagnostics volume trends, and the durability of its data/licensing business. Traders often bid up names with strong recent momentum into earnings, particularly when expectations are for “solid results” and the stock has been sensitive to updates on contract visibility and commercialization pace.

Analyst activity also stayed active into the session, including a TD Cowen note that lowered Tempus’ price target to $76 from $88 while keeping a Hold rating. Even when a target is reduced, a reiterated rating and ongoing sector optimism can keep buyers engaged—especially when the new target still sits well above the current price and earnings are days away.